Restricted accessResearch articleFirst published online 2015-02
Emodin Suppresses Maintenance of Stemness by Augmenting Proteosomal Degradation of Epidermal Growth Factor Receptor/Epidermal Growth Factor Receptor Variant III in Glioma Stem Cells
There is a growing body of evidence that small subpopulations of cells with stem cell-like characteristics within most solid tumors are responsible for the malignancy of aggressive cancer cells and that targeting these cells might be a good therapeutic strategy to reduce the risk of tumor relapse after therapy. Here, we examined the effects of emodin (1,3,8-trihydroxy-6-methylanthraquinone), an active component of the root and rhizome of Rheum palmatum that has several biological activities, including antitumor effects, on primary cultured glioma stem cells (GSCs). Emodin inhibited the self-renewal activity of GSCs in vitro as evidenced by neurosphere formation, limiting dilution, and soft agar clonogenic assays. Emodin inhibited the maintenance of stemness by suppressing the expression of Notch intracellular domain, nonphosphorylated β-catenin, and phosphorylated STAT3 proteins. In addition, treatment with emodin partially induced apoptosis, reduced cell invasiveness, and sensitized GSCs to ionizing radiation. Intriguingly, emodin induced proteosomal degradation of epidermal growth factor receptor (EGFR)/EGFR variant III (EGFRvIII) by interfering with the association of EGFR/EGFRvIII with heat shock protein 90, resulting in the suppression of stemness pathways. Based on these data, we propose that emodin could be considered as a potent therapeutic adjuvant that targets GSCs.
Get full access to this article
View all access options for this article.
References
1.
FurnariFB, FentonT, BachooRM, MukasaA, StommelJM, SteghA, HahnWC, LigonKL, LouisDN, et al. (2007). Malignant astrocytic glioma: genetics biology, and paths to treatment. Genes Dev, 21:2683–2710.
2.
StuppR, MasonWP, van den BentMJ, WellerM, FisherB, TaphoornMJ, BelangerK, BrandesAA, MarosiC, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352:987–996.
3.
BaoS, WuQ, McLendonRE, HaoY, ShiQ, HjelmelandAB, DewhirstMW, BignerDD and RichJN. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444:756–760.
4.
JordanCT, GuzmanML and NobleM. (2006). Cancer stem cells. N Engl J Med, 355:1253–1261.
5.
LapidotT, SirardC, VormoorJ, MurdochB, HoangT, Caceres-CortesJ, MindenM, PatersonB, CaligiuriMA and DickJE. (1994). A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature, 367:645–648.
6.
Al-HajjM, WichaMS, Benito-HernandezA, MorrisonSJ and ClarkeMF. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A, 100:3983–3988.
7.
SinghSK, HawkinsC, ClarkeID, SquireJA, BayaniJ, HideT, HenkelmanRM, CusimanoMD and DirksPB. (2004). Identification of human brain tumour initiating cells. Nature, 432:396–401.
8.
Ricci-VitianiL, LombardiDG, PilozziE, BiffoniM, TodaroM, PeschleC and De MariaR. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature, 445:111–115.
9.
VisvaderJE and LindemanGJ. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 8:755–768.
10.
EramoA, Ricci-VitianiL, ZeunerA, PalliniR, LottiF, SetteG, PilozziE, LaroccaLM, PeschleC and De MariaR. (2006). Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ, 13:1238–1241.
11.
RichJN. (2007). Cancer stem cells in brain tumor biology. Cancer Res, 67:8980–8984.
12.
LiY, WichaMS, SchwartzSJ and SunD. (2011). Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem, 22:799–806.
13.
HuangQ, LuG, ShenHM, ChungMC and OngCN. (2007). Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev, 27:609–630.
14.
ChenYC, ShenSC, LeeWR, HsuFL, LinHY, KoCH and TsengSW. (2002). Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol, 64:1713–1724.
15.
Acevedo-DuncanM, RussellC, PatelS and PatelR. (2004). Aloe-emodin modulates PKC isozymes, inhibits proliferation, and induces apoptosis in U-373 MG glioma cells. Int Immunopharmacol, 4:1775–1784.
16.
SuYT, ChangHL, ShyueSK and HsuSL. (2005). Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol, 70:229–241.
17.
HuangQ, ShenHM, ShuiG, WenkMR and OngCN. (2006). Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res, 66:5807–5815.
18.
KwakHJ, ParkMJ, ParkCM, MoonSI, YooDH, LeeHC, LeeSH, KimMS, LeeHW, et al. (2006). Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer, 118:2711–2720.
19.
LuY, ZhangJ and QianJ. (2008). The effect of emodin on VEGF receptors in human colon cancer cells. Cancer Biother Radiopharm, 23:222–228.
20.
KawasakiBT, HurtEM, MistreeT and FarrarWL. (2008). Targeting cancer stem cells with phytochemicals. Mol Interv, 8:174–184.
21.
ParkCH, HahmER, ParkS, KimHK and YangCH. (2005). The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett, 579:2965–2971.
22.
JaiswalAS, MarlowBP, GuptaN and NarayanS. (2002). Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene, 21:8414–8427.
23.
WangZ, ZhangY, BanerjeeS, LiY and SarkarFH. (2006). Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer, 106:2503–2513.
24.
KakaralaM, BrennerDE, KorkayaH, ChengC, TaziK, GinestierC, LiuS, DontuG and WichaMS. (2010).Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat, 122:777–785.
25.
LiY, ZhangT, KorkayaH, LiuS, LeeHF, NewmanB, YuY, ClouthierSG, SchwartzSJ, WichaMS and SunD. (2010). Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res, 16:2580–2590.
26.
LiXX, DongY, WangW, WangHL, ChenYY, ShiGY, YiJ and WangJ. (2013). Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma. Stem Cells Dev, 22:554–566.
27.
SoedaA, ParkM, LeeD, MintzA, Androutsellis-TheotokisA, McKayRD, EnghJ, IwamaT, KunisadaT, et al. (2009). Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene, 28:3949–3959.
28.
MellinghoffIK, WangMY, VivancoI, KoganHaas-DA, ZhuS, DiaEG, LuKV, YoshimotoK, HuangJH, et al. (2006). Molecular determinants of the response of glioblastoma to EGFR kinase inhibitors. N Engl J Med, 353:2012–2024.
29.
GieseA, BjerkvigR, BerensME and WestphalM. (2003). Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol, 21:1624–1636.
30.
YamoutpourF, BodempudiV, ParkSE, PanW, MauzyMJ, KratzkeRA, DudekA, PotterDA, WooRA, et al. (2008). Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther, 7:3586–3597.
31.
WangJ, WakemanTP, LathiaJD, HjelmelandAB, WangXF, WhiteRR, RichJN and SullengerBA. (2010). Notch promotes radioresistance of glioma stem cells. Stem Cells, 28:17–28.
32.
DickeyJS, RedonCE, NakamuraAJ, BairdBJ, SedelinikovaOA and BonnerWM. (2009). H2AX: functional roles and potential applications. Chromosoma, 118:683–692.
33.
YanYY, ZhengLS, ZhangX, ChenLK, SinghS, WangF, ZhangJY, LiangYJ, DaiCL, et al. (2011). Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. Mol Pharm, 8:1687–1697.
34.
XuW, MimnaughE, RosserMF, NicchittaC, MarcuM, YardenY and NeckersL. (2001). Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem, 276:3702–3708.
35.
AhsanA, RamanandSG, WhiteheadC, HinikerSM, RehemtullaA, PrattWB, JollyS, GouveiaC, TruongK, et al. (2012). Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia, 14:670–677.
36.
LavictoireSJ, ParolinDA, KlimowiczAC, KellyJF and LorimerIA. (2003). Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem, 278:5292–5299.
37.
YoonCH, KimMJ, KimRK, LimEJ, ChoiKS, AnS, HwangSG, KangSG, SuhY, ParkMJ and LeeSJ. (2012). c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene, 31:4655–4666.
38.
KimY, KimKH, LeeJ, LeeYA, KimM, LeeSJ, ParkK, YangH, JinJ, et al. (2012). Wnt activation is implicated in glioblastoma radioresistance. Lab Invest, 92:466–473.
39.
GarnerJM, FanM, YangCH, DuZ, SimsM, DavidoffAM and PfefferLM. (2013). Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem, 288:26167–26176.
40.
HatanpaaKJ, BurmaS, ZhaoD and HabibAA. (2010). Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia, 12:675–684.
41.
MukherjeeB, McEllinB, CamachoCV, TomimatsuN, SirasanagandalaS, NannepagaS, HatanpaaKJ, MickeyB, MaddenC, et al. (2009). EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res, 69:4252–4259.
42.
HuangPH, MukasaA, BonaviaR, FlynnRA, BrewerZE, CaveneeWK, FurnariFB and WhiteFM. (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A, 104:12867–12872.
43.
Del VecchioCA, GiacominiCP, VogelH, JensenKC, FlorioT, MerloA, PollackJR and WongAJ. (2013). EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene, 32:2670–2681.
44.
TrepelJ, MollapourM, GiacconeG and NeckersL. (2010). Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer, 10:537–549.
45.
MateiD, SatpathyM, CaoL, LaiYC, NakshatriH and NonnerDB. (2007). The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J Biol Chem, 282:445–453.
46.
ShimamuraT, LiD, JiH, HaringsmaHJ, LinikerE, BorgmanCL, LowellAM, MinamiY, McNamaraK, et al. (2008). Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res, 68:5827–5838.
47.
SauvageotCM, WeatherbeeJL, KesariS, WintersSE, BarnesJ, DellagattaJ, RamakrishnaNR, StilesCD, KungAL, et al. (2009). Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol, 11:109–121.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
